10

10.1158/0008-5472.CAN-17-1615 [PMC free article] [PubMed] [CrossRef] [Google Scholar] 41. different impacts on clinical outcomes. Furthermore, UHRF1 expression in LIHC and THYM showed an opposite correlation with biomarkers from monocyte, dendritic cell, Th1 and T cell exhaustion. Mechanism investigations revealed that RP11-424C20.2/UHRF1 axis regulated immune escape of LIHC and THYM at least partly through IFN–mediated CLTA-4 and PD-L1 pathway. These findings demonstrate a disparate role of RP11-424C20.2/UHRF1 axis in LIHC and THYM via regulating immune infiltrates, and also indicate a therapeutic value for UHRF1 inhibitors in combination with anti-PD-L1/CLTA-4 blockade. promotes silencing of tumor suppressor genes and predicts outcome in hepatoblastoma. Clin Epigenetics. 2018; 10:27. 10.1186/s13148-018-0462-7 [PMC free article] [PubMed] [CrossRef] [Google Scholar] 19. Taniue K, Kurimoto A, Sugimasa H, Nasu E, Takeda Y, Iwasaki K, Nagashima T, Okada-Hatakeyama M, Oyama M, Kozuka-Hata H, Hiyoshi M, Kitayama J, Negishi L, et al.. Long noncoding RNA UPAT promotes colon tumorigenesis by inhibiting degradation of UHRF1. Proc Natl Acad Sci USA. 2016; 113:1273C78. 10.1073/pnas.1500992113 [PMC free article] [PubMed] [CrossRef] [Google Scholar] 20. Liu X, Ou H, Xiang L, Li X, Huang Y, Yang D. Elevated UHRF1 expression contributes to poor prognosis by promoting cell proliferation and metastasis in hepatocellular carcinoma. Oncotarget. 2017; 8:10510C22. 10.18632/oncotarget.14446 [PMC free article] [PubMed] [CrossRef] [Google Scholar] 21. He H, Lee C, Kim JK. UHRF1 depletion sensitizes retinoblastoma cells to chemotherapeutic drugs via downregulation of XRCC4. Cell Death Dis. 2018; 9:164. 10.1038/s41419-017-0203-4 [PMC free article] [PubMed] [CrossRef] [Google Scholar] 22. Ivashkiv LB. IFN: signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy. Nat Rev Immunol. 2018; 18:545C58. 10.1038/s41577-018-0029-z [PMC free article] [PubMed] [CrossRef] [Google Scholar] 23. Garcia-Diaz A, Shin DS, Moreno BH, Saco J, Escuin-Ordinas H, Rodriguez GA, Zaretsky JM, Sun L, Hugo W, Wang X, Parisi G, Saus CP, Torrejon DY, et al.. Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression. Cell Rep. 2017; 19:1189C201. 10.1016/j.celrep.2017.04.031 [PMC free article] [PubMed] [CrossRef] [Google Scholar] 24. Wen YZ, Zheng LL, Qu LH, Ayala FJ, Lun ZR. Pseudogenes are not pseudo any more. RNA Biol. 2012; 9:27C32. 10.4161/rna.9.1.18277 [PubMed] [CrossRef] [Google Scholar] 25. An Y, Furber KL, Ji S. Pseudogenes regulate parental gene expression via Butoconazole ceRNA network. J Cell Mol Med. 2017; 21:185C92. 10.1111/jcmm.12952 [PMC free article] [PubMed] [CrossRef] [Google Scholar] 26. Li RK, Gao J, Guo LH, Huang GQ, Luo WH. PTENP1 acts as a ceRNA to regulate PTEN by sponging miR-19b and explores the biological role of PTENP1 in breast cancer. Cancer Gene Ther. 2017; 24:309C15. 10.1038/cgt.2017.29 [PubMed] [CrossRef] [Google Scholar] 27. Gao L, Ren W, Zhang L, Li S, Kong X, Zhang H, Dong J, Cai G, Jin C, Zheng D, Zhi K. PTENp1, a natural sponge of miR-21, mediates PTEN expression to inhibit the proliferation of oral squamous cell carcinoma. Mol Carcinog. 2017; 56:1322C34. 10.1002/mc.22594 [PubMed] [CrossRef] [Google Scholar] 28. Yu G, Yao W, Gumireddy K, Li A, Wang J, Xiao W, Chen K, Xiao H, Li H, Tang K, Ye Z, Huang Q, Xu H. Pseudogene PTENP1 functions as a competing endogenous RNA to suppress clear-cell renal cell carcinoma progression. Mol Cancer Ther. 2014; 13:3086C97. 10.1158/1535-7163.MCT-14-0245 [PMC free article] [PubMed] [CrossRef] [Google Scholar] 29. Chen R, Zhang M, Liu W, Chen H, Cai T, Xiong H, Sheng X, Liu S, Peng J, Wang F, Chen H, Lin W, Xu X, et al.. Estrogen affects the negative feedback loop of PTENP1-miR200c to inhibit PTEN expression in the development of endometrioid endometrial carcinoma. Cell Death Dis. 2018; 10:4. 10.1038/s41419-018-1207-4 [PMC free article] [PubMed] [CrossRef] [Google Scholar] 30. Zhang ZY, Zhu B, Zhao XW, Zhan YB, Bao JJ, Zhou JQ, Zhang FJ, Yu B, Liu J, Wang YM, Bai YH, Hong J, Liu XZ. Regulation of UHRF1 by microRNA-378 modulates medulloblastoma cell proliferation and Mouse monoclonal to CARM1 apoptosis. Oncol Rep. 2017; 38:3078C84. 10.3892/or.2017.5939 [PubMed] [CrossRef] [Google Scholar] 31. Fridman WH, Pags F, Sauts-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 2012; 12:298C306. 10.1038/nrc3245 [PubMed] [CrossRef] [Google Scholar] 32. Zhang H, Liu H, Shen Z, Lin C, Wang X, Qin J, Qin X, Xu J,.2018; 48:107C119.e4. showed a strong association of UHRF1 with immune-related biological processes. We also observed that UHRF1 expression significantly correlated with immune infiltration, and different types of tumor-infiltrating immune cells displayed different effects on medical results. Furthermore, UHRF1 manifestation in LIHC and THYM showed an opposite correlation with biomarkers from monocyte, dendritic cell, Th1 and T cell exhaustion. Mechanism investigations exposed that RP11-424C20.2/UHRF1 axis regulated immune escape of LIHC and THYM at least partly through IFN–mediated CLTA-4 and PD-L1 pathway. These findings demonstrate a disparate part of RP11-424C20.2/UHRF1 axis in LIHC and THYM via regulating immune infiltrates, and also indicate a therapeutic value for UHRF1 inhibitors in combination with anti-PD-L1/CLTA-4 blockade. promotes silencing of tumor suppressor genes and predicts end result in hepatoblastoma. Clin Epigenetics. 2018; 10:27. 10.1186/s13148-018-0462-7 [PMC free article] [PubMed] [CrossRef] [Google Scholar] 19. Taniue K, Kurimoto A, Sugimasa H, Nasu E, Takeda Y, Iwasaki K, Nagashima T, Okada-Hatakeyama M, Oyama M, Kozuka-Hata H, Hiyoshi M, Kitayama J, Negishi L, et al.. Long noncoding RNA UPAT promotes colon tumorigenesis by inhibiting degradation of UHRF1. Proc Natl Acad Sci USA. 2016; 113:1273C78. 10.1073/pnas.1500992113 [PMC free article] [PubMed] [CrossRef] [Google Scholar] 20. Liu X, Ou H, Xiang L, Li X, Huang Y, Yang D. Elevated UHRF1 manifestation contributes to poor prognosis by advertising cell proliferation and metastasis in hepatocellular carcinoma. Oncotarget. 2017; 8:10510C22. 10.18632/oncotarget.14446 [PMC free article] [PubMed] [CrossRef] [Google Scholar] 21. He H, Lee C, Kim JK. UHRF1 depletion sensitizes retinoblastoma cells to chemotherapeutic medicines via downregulation of XRCC4. Cell Death Dis. 2018; 9:164. 10.1038/s41419-017-0203-4 [PMC free article] [PubMed] [CrossRef] [Google Scholar] 22. Ivashkiv LB. IFN: signalling, epigenetics and tasks in immunity, rate of metabolism, disease and malignancy immunotherapy. Nat Rev Immunol. 2018; 18:545C58. 10.1038/s41577-018-0029-z [PMC free article] [PubMed] [CrossRef] [Google Scholar] 23. Garcia-Diaz A, Shin DS, Moreno BH, Saco J, Escuin-Ordinas H, Rodriguez GA, Zaretsky JM, Sun L, Hugo W, Wang X, Parisi G, Saus CP, Torrejon DY, et al.. Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Manifestation. Cell Rep. 2017; 19:1189C201. 10.1016/j.celrep.2017.04.031 [PMC free article] [PubMed] [CrossRef] [Google Scholar] 24. Wen YZ, Zheng LL, Qu Butoconazole LH, Ayala FJ, Lun ZR. Pseudogenes are not pseudo any more. RNA Biol. 2012; 9:27C32. 10.4161/rna.9.1.18277 [PubMed] [CrossRef] [Google Scholar] 25. An Y, Furber KL, Ji S. Pseudogenes regulate parental gene manifestation via ceRNA network. J Cell Mol Med. 2017; 21:185C92. 10.1111/jcmm.12952 [PMC free article] [PubMed] [CrossRef] [Google Scholar] 26. Li RK, Gao J, Guo LH, Huang GQ, Luo WH. PTENP1 functions as a ceRNA to regulate PTEN by sponging miR-19b and explores the biological part of PTENP1 in breast cancer. Tumor Gene Ther. 2017; 24:309C15. 10.1038/cgt.2017.29 [PubMed] [CrossRef] [Google Scholar] 27. Gao L, Ren W, Zhang L, Li S, Kong X, Zhang H, Dong J, Cai G, Jin C, Zheng D, Zhi K. PTENp1, a natural sponge of miR-21, mediates PTEN manifestation to inhibit the proliferation of oral squamous cell carcinoma. Mol Carcinog. 2017; 56:1322C34. 10.1002/mc.22594 [PubMed] Butoconazole [CrossRef] [Google Scholar] 28. Yu G, Yao W, Gumireddy K, Li A, Wang J, Xiao W, Chen K, Xiao H, Li H, Tang K, Ye Z, Huang Q, Xu H. Pseudogene PTENP1 functions as a competing endogenous RNA to suppress clear-cell renal cell carcinoma progression. Mol Malignancy Ther. 2014; 13:3086C97. 10.1158/1535-7163.MCT-14-0245 [PMC free article] [PubMed] [CrossRef] [Google Scholar] 29. Chen R, Zhang M, Liu W, Chen H, Cai T, Xiong H, Sheng X, Liu S, Peng J, Wang F, Chen H, Lin W, Xu X, et al.. Estrogen affects the negative opinions loop of PTENP1-miR200c to inhibit PTEN manifestation in the development of endometrioid endometrial carcinoma. Cell Death Dis. 2018; 10:4. 10.1038/s41419-018-1207-4 [PMC free article] [PubMed] [CrossRef] [Google Scholar] 30. Zhang ZY, Zhu B, Zhao XW, Zhan YB, Bao JJ, Zhou JQ, Zhang FJ, Yu B, Liu J, Wang YM, Bai YH, Hong J, Liu XZ. Rules of UHRF1 by microRNA-378 modulates medulloblastoma cell proliferation and apoptosis. Oncol Rep. 2017; 38:3078C84. 10.3892/or.2017.5939 [PubMed] [CrossRef] [Google Scholar] 31. Fridman WH, Pags F, Sauts-Fridman C, Galon J. The immune contexture in human being tumours: impact on medical end result. Nat Rev Malignancy. 2012; 12:298C306. 10.1038/nrc3245 [PubMed] [CrossRef].